AstraZeneca gets a $500M antibody contract, yet key questions still loom for Trump's new favorite treatment
As President Trump touts the supposed ‘miracle‘ effects of Regeneron’s antibody treatments on Twitter and Fox News, the federal government is upping its investment in the technology, putting a half billion dollars behind a third company developing antibodies to fight Covid-19.
HHS announced Friday they would spend $486 million to help AstraZeneca develop their monoclonal antibody cocktail. Although the agency touts the potential of the cocktail, known as AZD7442, to both treat and prevent Covid-19, the government appears to be valuing it primarily for its potential as prevention.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.